Marshall Wace’s Zevra Therapeutics ZVRA Stock Holding History

Marshall Wace’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	70,286 -369,666	-84%	-$4.11M	﹤0.01%	2186
2026 Q1	$4.1M	Sell	439,952 -229,790	-34%	-$2.07M	﹤0.01%	1397
2025 Q4	$6M	Sell	669,742 -242,557	-27%	-$2.29M	0.01%	1073
2025 Q3	$8.68M	Buy	+912,299	New	+$9.15M	0.01%	970
2024 Q4	–	Sell	-52,077	Closed	-$361K	–	3071
2024 Q3	$361K	Buy	+52,077	New	+$353K	﹤0.01%	2057
2021 Q4	–	Sell	-109,936	Closed	-$1.03M	–	4351
2021 Q3	$1.03M	Buy	109,936 +92,783	+541%	+$935K	﹤0.01%	2001
2021 Q2	$220K	Buy	+17,153	New	+$184K	﹤0.01%	2419

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's ZVRA Position: Q2 2026 in Review

Marshall Wace reduced its Zevra Therapeutics (ZVRA) stake by 84% in Q2 2026, selling an estimated $4.11M and leaving 70,286 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2186.

Marshall Wace first reported a position in ZVRA in Q2 2021 and has held it in 7 quarters since. The position peaked at $8.68M in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Marshall Wace held 70,286 shares of Zevra Therapeutics worth $1.01M as of Q2 2026.
Marshall Wace sold 369,666 Zevra Therapeutics shares in Q2 2026, an estimated $4.11M.
Zevra Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2186 holding.
Marshall Wace first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 7 quarters since.
Marshall Wace's Zevra Therapeutics position peaked at $8.68M in Q3 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.